Monitoring and Management of Thyroid Autoimmunity in Pregnancy

Risk Assessment

• Women who are positive for thyroid antibodies but have normal TSH, T3, and T4 are at a significant risk of developing hypothyroidism during gestation and therefore require close thyroid monitoring every 4–6 weeks throughout pregnancy. 1

Monitoring Protocol

• The Endocrine Society recommends measuring TSH (at minimum) at least every 4–6 weeks in pregnant women with thyroid autoimmunity to detect early progression to hypothyroidism. [1][2]3

Treatment Initiation

• If TSH exceeds pregnancy‑specific reference limits (> 2.5 mIU/L in the first trimester or > 3.0 mIU/L in the second/third trimesters), levothyroxine therapy should be started immediately. [1][2]
• The Endocrine Society guidelines advise thyroid‑hormone (T4) replacement for subclinical hypothyroidism in antibody‑positive women because the potential obstetrical benefits outweigh the risks. [1][2]

Pre‑Conception Optimization

• Prior to conception, TSH should be ≤ 2.5 mIU/L in any woman with detectable thyroid antibodies or any thyroid dysfunction. [1][2]

Common Mistakes to Avoid

• Assuming that a normal baseline thyroid function eliminates the need for intervention is incorrect; regular monitoring itself constitutes the essential intervention. 1
• Using non‑pregnant reference ranges for TSH during pregnancy is inappropriate; pregnancy‑specific ranges are lower (first‑trimester TSH < 2.5 mIU/L). [1][2]

Impact of Untreated or Inadequately Treated Hypothyroidism

• Untreated or inadequately treated hypothyroidism in pregnancy is associated with serious fetal adverse effects, including impaired neurological development, higher rates of preterm birth, and low birth weight. [1][4]
• Even subclinical hypothyroidism (elevated TSH with normal T4) in antibody‑positive women is linked to adverse maternal and fetal outcomes. 1

Guideline Recommendations and Evidence Strength

• The 2012 Endocrine Society Clinical Practice Guidelines provide Level A (good evidence) recommendations for routine monitoring of euthyroid women with thyroid autoimmunity throughout pregnancy. [1][2]